# Special Issue

# New Insights of Anti-cancer Immunity and Cancer Immune Evasion

## Message from the Guest Editor

Cancer cells and malignant tumors operate a range of biochemical pathways which allow them to produce and activate proteins (known as immune checkpoints) and small molecular weight compounds capable of suppressing anti-cancer activities of immune cells. Recent evidence clearly demonstrated that immune evasion mechanisms operated by cancer cells include complex machinery. In order to successfully treat cancer employing patients' immune system and helping it to deal with malignancies, a deep understanding of molecular basis of cancer immune evasion networks is required. The aim of this collection is to put together the manuscripts highlighting new discoveries and advances in anti-tumor immunity and cancer immune evasion machinery. We welcome submissions of research articles and short reports, clinical studies and clinical trials associated with cancer immune evasion machinery, anti-cancer immunity and immunotherapy of cancer. We also welcome expert reviews covering the aspects mentioned above.

## Guest Editor

Dr. Vadim Sumbayev

Medway School of Pharmacy, Universities of Kent and Greenwich, Chatham, UK

## Deadline for manuscript submissions

31 March 2025

# Immuno

**an Open Access Journal by MDPI**

**Impact Factor 2.1**
**CiteScore 2.6**

mdpi.com/journal/immuno

# About the Journal

## Message from the Editor-in-Chief

### Editor-in-Chief

Prof. Dr. Toshihiko Torigoe
Department of Pathology, Sapporo Medical University School of Medicine, S-1, W-17, Chuo-ku, Sapporo 060-8556, Japan

### Author Benefits

**Open Access:**
free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:**
indexed within ESCI (Web of Science), Scopus, EBSCO, and other databases.

**Rapid Publication:**
manuscripts are peer-reviewed and a first decision is provided to authors approximately 28.1 days after submission; acceptance to publication is undertaken in 5.5 days (median values for papers published in this journal in the first half of 2024).